Lecap Asset Management Ltd. Has $1.40 Million Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Lecap Asset Management Ltd. reduced its stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 23.9% during the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 8,481 shares of the company's stock after selling 2,659 shares during the period. Lecap Asset Management Ltd.'s holdings in Zoetis were worth $1,396,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. Schroder Investment Management Group raised its holdings in Zoetis by 2.6% during the 4th quarter. Schroder Investment Management Group now owns 245,726 shares of the company's stock worth $40,036,000 after buying an additional 6,169 shares during the period. Vanguard Group Inc. raised its holdings in Zoetis by 0.3% during the 4th quarter. Vanguard Group Inc. now owns 41,366,877 shares of the company's stock worth $6,739,905,000 after buying an additional 120,158 shares during the period. Portside Wealth Group LLC raised its holdings in Zoetis by 24.7% during the 1st quarter. Portside Wealth Group LLC now owns 33,709 shares of the company's stock worth $5,550,000 after buying an additional 6,672 shares during the period. Oppenheimer & Co. Inc. raised its holdings in Zoetis by 72.4% during the 4th quarter. Oppenheimer & Co. Inc. now owns 93,114 shares of the company's stock worth $15,171,000 after buying an additional 39,114 shares during the period. Finally, OFI Invest Asset Management acquired a new stake in Zoetis during the 4th quarter worth approximately $37,298,000. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Price Performance

NYSE:ZTS opened at $157.41 on Thursday. Zoetis Inc. has a 1-year low of $139.70 and a 1-year high of $200.33. The company has a current ratio of 1.74, a quick ratio of 1.04 and a debt-to-equity ratio of 1.12. The firm has a fifty day simple moving average of $160.10 and a 200 day simple moving average of $163.02. The stock has a market capitalization of $70.08 billion, a PE ratio of 28.26, a P/E/G ratio of 2.62 and a beta of 0.94.

Zoetis (NYSE:ZTS - Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.08. Zoetis had a net margin of 27.12% and a return on equity of 55.48%. The business had revenue of $2.22 billion during the quarter, compared to analysts' expectations of $2.20 billion. During the same period last year, the business earned $1.38 earnings per share. The firm's revenue was up 1.4% on a year-over-year basis. On average, research analysts expect that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Friday, July 18th will be paid a $0.50 dividend. The ex-dividend date is Friday, July 18th. This represents a $2.00 annualized dividend and a dividend yield of 1.27%. Zoetis's dividend payout ratio is presently 35.91%.

Insider Activity at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 652 shares of Zoetis stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $170.00, for a total transaction of $110,840.00. Following the completion of the transaction, the executive vice president now directly owns 15,129 shares of the company's stock, valued at $2,571,930. The trade was a 4.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.18% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several analysts have commented on ZTS shares. UBS Group dropped their target price on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a report on Wednesday, May 7th. Stifel Nicolaus cut shares of Zoetis from a "buy" rating to a "hold" rating and decreased their price target for the stock from $165.00 to $160.00 in a research note on Wednesday, June 18th. Piper Sandler raised their price target on shares of Zoetis from $205.00 to $210.00 and gave the stock an "overweight" rating in a research note on Monday, May 12th. Finally, Wall Street Zen raised shares of Zoetis from a "hold" rating to a "buy" rating in a research note on Friday, March 7th. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Buy" and a consensus price target of $212.13.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.